Innovating Works

iMM

Mostrando 1 al 20 de 170 resultados
LeishMal: Immune-mediated reciprocal impact of concomitant infection by Plasmodium and Leishmania parasites INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES tramitó un HORIZON EUROPE: HORIZON-WIDERA-2023-TALENTS-02 Malaria and Visceral Leishmaniasis (VL) are prevalent parasitic diseases presenting substantial healthcare challenges in tropical and subtro...
2024-06-01 - 2026-05-31 | Financiado
LeishMal: Immune mediated reciprocal impact of concomitant infection by Plasmodium and Leishmania parasites Malaria and Visceral Leishmaniasis (VL) are prevalent parasitic diseases presenting substantial healthcare challenges in tropical and subtro...
2024-05-29 - 2026-05-31 | Financiado
CD-ResOMics: Elucidating the cellular basis of therapeutic resistance in Crohn's disease INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES tramitó un HORIZON EUROPE: HORIZON-WIDERA-2023-TALENTS-02 Crohn´s Disease (CD) is a chronic inflammatory disease that affects the gastrointestinal tract, affecting millions of people worldwide and p...
2024-05-23 - 2026-06-15 | Financiado
BIOinFILM: Shedding light on the key molecular determinants regulating 3D diffusion and activity of antimicrobi... INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Bacterial biofilms are associated with approximately 1.7 million hospital-acquired infections annually in the United States, incurring an an...
2024-05-22 - 2027-08-31 | Financiado
PoEMM: Plasmodium Exploitation of Liver-specific Methionine Metabolism INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Malaria remains the most serious parasitic infectious disease, killing one child every two minutes. Plasmodium infection starts when the fem...
2024-05-22 - 2026-08-31 | Financiado
BIOMICS: Fostering Excellent Research, Training and Innovation in Biomedical Data Science INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES tramitó un HORIZON EUROPE: HORIZON-WIDERA-2023-ACCESS-02 The Instituto de Medicina Molecular João Lobo Antunes (iMM) is a leading European institute in basic biomedical research, now establishing a...
2024-05-22 - 2027-09-30 | Financiado
PANERIS: Pan-European Network for Neuroscience Research Infrastructure and Strengthening of Support capacitie... INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES participó en un HORIZON EUROPE: HORIZON-WIDERA-2023-ACCESS-04 Current challenges in European Research and Innovation (R&I) infrastructure in neuroscience include barriers for collaboration, funding gaps...
2024-03-26 - 2026-04-30 | Financiado
TissueLymphOmics: Cellular crosstalk driving Tertiary Lymphoid Structure formation across tissues INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Formation of Tertiary Lymphoid Structures (TLS) is a recurring consequence of chronic tissue inflammation and autoimmunity, as well as sever...
2024-03-04 - 2026-03-31 | Financiado
immSC-AgingFate: The Interplay of Aging, Immune Signaling and Stem Cell Function INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES tramitó un HORIZON EUROPE: ERC-2023-COG Adult stem cells (SCs) sustain tissue renewal and repair throughout life. The SC niche is fundamental in the regulation of SC function and a...
2024-01-29 - 2029-02-28 | Financiado
EvaMobs: Evolvable and rapidly adaptable monobodies: a broad-spectrum antiviral platform INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-03 With progress in globalization, expansion of human populations into natural habitats, and aggravation of climate change comes an increased r...
2023-11-23 - 2028-12-31 | Financiado
PASSAGE: Plasmodium liver stage schizogony: high replication and genetic diversity INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES tramitó un HORIZON EUROPE: ERC-2022-ADG A world free of malaria is certainly a desirable goal. However, in spite of the significant incidence reduction achieved globally between 20...
2023-05-31 - 2028-05-31 | Financiado
HCMSpliceAOC: Molecular design and application of splice-switching antibody-oligonucleotide conjugate for hypertro... INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES tramitó un HORIZON EUROPE: HORIZON-WIDERA-2022-TALENTS-04 Familial hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and is predominately caused by mutations in genes that...
2023-05-15 - 2025-05-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.